Gene Deletion of the Kinin Receptor B1 Attenuates Cardiac Inflammation and Fibrosis during the Development of Experimental Diabetic Cardiomyopathy

Dirk Westermann,1 Thomas Walther,1 Konstantinos Savvatis,1 Felicitas Escher,1 Meike Sobirey,1 Alexander Riad,1 Michael Bader,2 Heinz-Peter Schultheiss,1 and Carsten Tschöpe1

OBJECTIVE—Diabetic cardiomyopathy is associated with increased mortality in patients with diabetes. The underlying pathology of this disease is still under discussion. We studied the role of the kinin B1 receptor on the development of experimental diabetic cardiomyopathy.

RESEARCH DESIGN AND METHODS—We utilized B1 receptor knockout mice and investigated cardiac inflammation, fibrosis, and oxidative stress after induction of streptozotocin (STZ)-induced diabetes. Furthermore, the left ventricular function was measured by pressure-volume loops after 8 weeks of diabetes.

RESULTS—B1 receptor knockout mice showed an attenuation of diabetic cardiomyopathy with improved systolic and diastolic function in comparison with diabetic control mice. This was associated with a decreased activation state of the mitogen-activated protein kinase p38, less oxidative stress, as well as normalized cardiac inflammation, shown by fewer invading cells and no increase in matrix metalloproteinase-9 as well as the chemokine CXCL-5. Furthermore, the profibrotic connective tissue growth factor was normalized, leading to a reduction in cardiac fibrosis despite severe hyperglycemia in mice lacking the B1 receptor.

CONCLUSIONS—These findings suggest that the B1 receptor is detrimental in diabetic cardiomyopathy in that it mediates inflammatory and fibrotic processes. These insights might have useful implications on future studies utilizing B1 receptor antagonists for treatment of human diabetic cardiomyopathy.

Diabetes 58:1373–1381, 2009

Diabetic cardiomyopathy, as it occurs in patients with diabetes, carries a substantial risk concerning the subsequent development of heart failure and increased mortality (1). Different pathophysiological stimuli are involved in its development and mediate tissue injury leading to left ventricular systolic and diastolic dysfunction. Accumulation of cardiac fibrosis with distinct changes in the regulation of the extracellular matrix (2,3), excessive generation of reactive oxygen species (4), and cardiac inflammation (5,6), characterized by increased levels of proinflammatory cytokines and transendothelial migration of immunocompetent cells, plays a role in the manifestation of diabetic cardiomyopathy. Experimental stimulation of the local tissue kallikrein-kinin system has been shown to be beneficial in different forms of cardiomyopathies (7–11). Most of these effects are attributed to the kinin B2 receptor (B2R), while the role of the kinin B1 receptor (B1R) in cardiac failure is still under discussion. In contrast to the B2R, which is constitutively expressed in the cardiac tissue, the B1R is expressed at very low levels under basal conditions. Nevertheless, it is highly inducible under pathological conditions by pathological mediators such as bacterial lipopolysaccharide (12), cytokines (13), and ischemia but also by hyperglycemia (14), as can be shown in different animal models of cardiomyopathy. Also, in endomyocardial biopsies of patients with end-stage heart failure, this upregulation could be demonstrated and correlated with increased expression of proinflammatory cytokines in those patients (15). Whether B1R upregulation is cardioprotective, parallel to that of the B2R (16,17), or is cardiotoxic (13,18,19) remains debated. To further clarify the role of the B1R in the pathogenesis of diabetic cardiomyopathy, we investigated the left ventricular function in an animal model of streptozotocin (STZ)-induced type 1 diabetes using B1R knockout mice. Furthermore, changes in the left ventricular remodeling, inflammation, and oxidative stress were analyzed.

RESEARCH DESIGN AND METHODS

Twenty-five B1R knockout mice (B1R−/−) on a C57BL6 genetic background and 25 littermates (B1R+/+) aged 2 months were obtained from the Max-Delbrück Center for Molecular Medicine (Berlin-Buch, Germany) (13). Diabetes was induced by injection of STZ (50 mg/kg i.p. for 5 days) in 15 B1R−/− (B1R−/−STZ) and 15 C57BL6 mice (B1R+/−STZ), while the others served as nondiabetic controls (B1R+/+ and control). Hyperglycemia (glucose >22 mmol/l) was confirmed 7 days later using a reflectance meter (Acutrend; Boehringer, Mannheim, Germany), as well as at the end of the study (glucose >30 mmol/l). The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publ. no. 85-23, revised 1985).

Surgical procedures and hemodynamic measurements. Eight weeks after induction of diabetes, left ventricular function was analyzed using pressure-volume loops. The animals were anesthetized (125 mg/g i.p. thiopeptol), intubated, and artificially ventilated. As described recently (20), a 1.2-F microconductance pressure catheter (SciSense, Ontario, Canada) was positioned in the left ventricle for registration of left ventricular pressure-volume loops in a closed-chest model. Indexes of cardiac function were derived from pressure-volume data obtained both at steady state and during transient preload reduction by occlusion. Systolic function was quantified by left ventricular end systolic pressure (mmHg), by dP/dtmax (mmHg/s), and by ejection fraction (%). Global cardiac function was quantified by the end systolic volume (μl), end diastolic volume (μl), stroke volume (μl), cardiac...
from measurements in the arteria carotis (22). Cardiac tissue was harvested and snap frozen for later measurements. All following measurements were performed in 10 animals per group.

**Histological measurements.** Immunohistochemistry was carried out using primary antibodies for collagen type 1 and type 3, the connective tissue growth factor (CTGF), the matrix-metalloproteinase-9 (MMP-9), and CD3, CD45, CD11b, CD45, and CD68 cells as well as nitrotyrosine and myeloperoxidase (MPO) (all from Serotec, Munich, Germany) followed by the DAKO

### TABLE 1

|                          | B1R+/+ | B1R−/− | B1R+/+−STZ | B1R−/−−STZ |
|--------------------------|--------|--------|------------|------------|
| Body weight (g)          | 27 ± 1 | 28 ± 1 | 17 ± 1*    | 17 ± 1*    |
| Glucose levels (mmol/l)  | 6 ± 0.2| 6 ± 0.2| 31 ± 2*    | 32 ± 2*    |
| Hemodynamic function     |        |        |            |            |
| Heart rate (beats/min)   | 465 ± 22 | 486 ± 32 | 302 ± 27* | 389 ± 35   |
| End diastolic volume (µl)| 53 ± 2 | 48 ± 4 | 49 ± 4    | 47 ± 3    |
| End systolic volume (µl) | 18 ± 4 | 15 ± 3 | 28 ± 5    | 23 ± 5    |
| Stroke volume (µl)       | 35 ± 6 | 31 ± 4 | 19 ± 6*   | 24 ± 5    |
| Cardiac output (ml/min)  | 16.1 ± 1 | 15.8 ± 1 | 6.3 ± 6*  | 9.3 ± 1†  |
| Cardiac output/body weight (ml · min⁻¹ · g⁻¹) | 0.61 ± 0.02 | 0.57 ± 0.04 | 0.41 ± 0.04* | 0.56 ± 0.03 |
| Left ventricular systolic pressure (mmHg) | 98 ± 4 | 103 ± 5 | 72 ± 5*  | 86 ± 6†  |
| dP/dt max (mmHg/s)       | 6,658 ± 346 | 6,858 ± 256 | 3,215 ± 201* | 5,214 ± 286† |
| Ejection fraction (%)    | 66 ± 4 | 64 ± 5 | 38 ± 7*  | 51 ± 4†  |
| Left ventricular diastolic pressure (mmHg) | 2.5 ± 1 | 2.8 ± 1 | 9.4 ± 2* | 4.4 ± 2† |
| dP/dt min, (mmHg/s)      | -5,866 ± 301 | -5,485 ± 285 | -2,348 ± 247* | -4,257 ± 244† |
| Left ventricular stiffness (ml⁻¹) | 0.027 ± 0.002 | 0.034 ± 0.002 | 0.127 ± 0.001* | 0.047 ± 0.004† |
| Mean blood pressure (mmHg) | 95 ± 4 | 98 ± 5 | 68 ± 7* | 88 ± 6† |

Data are means ± SE. Hemodynamic function of control mice (B1R+/+) or mice lacking the B1R (B1R−/−) under basal conditions and 8 weeks after induction of STZ-induced diabetes. *P < 0.05 vs. nondiabetic controls; †P < 0.05 vs. B1R+/+−STZ. dP/dt max, contractility; dP/dt min, relaxation.

Output (µl/min), the ratio of cardiac output to body weight (µl · min⁻¹ · g⁻¹), and heart rate (beats/min). Diastolic function was measured by left ventricular end diastolic pressure (mmHg), left ventricular pressure fall (dP/dt min) (mmHg/s), and diastolic stiffness. Diastolic stiffness was calculated from the end diastolic pressure-volume relationship [EDP = C · exp (b − Ved)] where b is for stiffness (21). Moreover, mean arterial blood pressure was analyzed from measurements in the arteria carotis (22). Cardiac tissue was harvested and snap frozen for later measurements. All following measurements were performed in 10 animals per group.

**Histological measurements.** Immunohistochemistry was carried out using primary antibodies for collagen type 1 and type 3, the connective tissue growth factor (CTGF), the matrix-metalloproteinase-9 (MMP-9), and CD3, CD45, CD11b, CD45, and CD68 cells as well as nitrotyrosine and myeloperoxidase (MPO) (all from Serotec, Munich, Germany) followed by the DAKO

**FIG. 1.** Representative pressure-volume loops during a preload reduction of control mice (B1R+/+) or mice lacking the B1R (B1R−/−) under basal conditions and 8 weeks after induction of STZ-induced diabetes. The thick black line at the bottom indicates the left ventricular stiffness, which is increased in B1R+/+−STZ (indicated by the thick black arrow).
Envision horseradish peroxidase technique (DAKO, Glostrup, Denmark). Histological costainings were performed using primary antibodies for CD68, tumor necrosis factor (TNF)-α (R&D Systems, Wiesbaden, Germany), sarcomeric actin, and TAB-1 (Cell Signaling Technology, Danvers, MA).

**RESULTS**

Eight weeks after induction of STZ-induced diabetes, glucose levels were found to be highly increased in B1R^+/−^-STZ and B1R^+/+^-STZ mice but did not differ between both diabetic groups. Body weight decreased in both groups when compared with controls (Table 1).

**Hemodynamic data.** Lack of B1R had no effect on cardiac function under normoglycemic conditions. The heart rate was significantly decreased in B1R^+/−^-STZ mice when compared with controls, due to the known effect of diabetic cardiac autonomy (24), while B1R^+/+^-STZ mice were not statistically different from their controls. No ventricular dilatation was demonstrated in either STZ group when compared with their controls, while stroke volume was smaller in STZ, which contributed to impaired cardiac output in comparison with the controls. This decline of cardiac output could be partly prevented by B1R.
Knockout but was still impaired when B1R\(^{-/-}\)-STZ mice were compared with controls. The systolic and diastolic parameters end systolic pressure, dP/dt\(_{\text{max}}\), and ejection fraction were significantly decreased; the end diastolic pressure as well as diastolic stiffness was increased when STZ was compared with the control group. However, the impairment in these parameters was much less pronounced in B1R\(^{-/-}\)-STZ mice (Table 1 and Fig. 1).

Cardiac inflammation and oxidative stress. In the myocardium of the diabetic mice, the mRNA abundance of the proinflammatory cytokines IL-1\(\beta\), IL-6, and TNF-\(\alpha\) as well as the chemokine CXCL-5 were significantly increased by B1R\(^{+/+}\)-STZ compared with controls (Fig. 2). This was associated with increased numbers of CD3\(^+\), CD11b\(^+\), CD45\(^+\), and CD68\(^+\) cells (Fig. 3) and the protein abundance of MMP-9 (Fig. 4). This upregulation was prevented by B1R\(^{-/-}\)-STZ, resulting in normalized levels compared with controls, again an effect that was reduced in B1R\(^{-/-}\)-STZ mice when compared with controls. Moreover, TAB-1 protein was significantly increased in diabetic wild-type compared with B1R\(^{-/-}\)-STZ mice (Fig. 6).

Kinin receptor regulation. The B1R mRNA was increased by STZ-induced diabetes in wild-type mice. The B2R mRNA was also increased due to diabetic condition in wild-type mice. In B1R\(^{-/-}\) animals, the B2R expression was higher compared with wild-type mice under basal conditions. Interestingly, there was no further B2R mRNA upregulation due to diabetic conditions as seen in wild-type mice (Fig. 2).
Cardiac fibrosis. CTGF was highly increased in diabetic animals. This increase in CTGF was accompanied by increased levels of collagen type 1 and 3, as an indicator of cardiac fibrosis. In contrast, CTGF was normalized in B1R+/+H11002/H11002-STZ, which translated into normalized collagen type 1 and type 3 levels as well, when compared with the controls (Fig. 7).

DISCUSSION
The salient finding of this study is that B1R gene deletion attenuates cardiac systolic and diastolic dysfunction in experimental diabetic cardiomyopathy. Diabetic cardiomyopathy is characterized by an increase in the phosphorylation state of the MAPK p38, which was associated with augmented cardiac inflammation, cardiac fibrosis, and oxidative stress in cardiac tissue. These changes were normalized in mice lacking the B1R, despite the occurrence of comparable severe hyperglycemia.

Experimental stimulation of the kallikrein-kinin system by gene transfer (25,26) and/or by the use of transgenic kallikrein overexpressing animals (10) attenuates diabetic cardiomyopathy. This is in agreement with other studies showing potent cardioprotective effects of the kallikrein-kinin system in animal models of ischemic (27–29), pressure overload (8), and septic (12) and hypertensive (9) cardiomyopathy. We, and others, using the STZ model of diabetes, were able to show that these cardiobiological effects of kallikrein-kinin mediate anti-inflammatory and antifibrotic effects and, furthermore, reduce oxidative stress (10,30,31) as well as improve glucose utilization and lipid metabolism (20,32). Both receptors of the system, the B1R and the B2R, are upregulated in the diabetic heart (14). The cardioprotective effects are mediated mainly by the B2R, since pharmacological inhibition of the B2R was seen to abolish these cardioprotective effects (31). The relationship between B1R and the development of heart failure is still under investigation. Recently, it was shown that the B1R may yield similar effects when compared with the B2R in an animal model of myocardial infarction (17). Nonetheless, other researchers have shown that a lack of the B1R reduced infarct size in ischemia reperfusion injury (19,33), a finding that indeed may imply an opposite function compared with that of the B2R. While there is good evidence that the B1R plays a detrimental role in autonomic diabetic nociception (34), obstructive nephropathy (35), and stroke (36) by modulating inflammatory

FIG. 4. Increased protein levels of oxidative stress (nitrotyrosine and MPO) as well as the MMP-9 in the cardiac tissue of B1R+/+STZ. Moreover, the figure shows protein levels and mRNA levels of eNOS and representative pictures of all groups for MPO and eNOS. *P < 0.05 vs. B1R+/+. (A high-quality digital representation of this figure is available in the online issue.)
processes and increasing inflammation, its role in the development of diabetic cardiomyopathy has not yet been directly investigated.

We demonstrated recently that diabetic cardiomyopathy is associated with increased cardiac inflammation (2,5,10). These inflammatory processes were associated with increased oxidative stress and cardiac fibrosis, all contributing to systolic and diastolic dysfunction under diabetic conditions. Since the B1R is known to be upregulated by IL-1β (37) and hyperglycemia (14,38) and mediate tissue

\[
\text{TNF-α} \quad \text{CD68} \\
\text{α-sarcomeric actin} \\
\text{DAPI} \\
\text{TNF-α} \quad \text{CD68} \\
\]

FIG. 5. Immunofluorescent stainings of cardiac tissue of a diabetic wild-type mouse with stainings for CD68, TNF-α, as well α-sarcomeric actin and DAPI (for cell nuclei) showing that TNF-α is secreted by inflammatory CD68⁺ cells. (A high-quality digital representation of this figure is available in the online issue.)

\[
\text{TAB1} \\
\text{P-p38} \\
\text{T-p38} \\
\text{B1R STZ +/+} \\
\text{B1R STZ +/+} \\
\]

FIG. 6. A: Immunofluorescent stainings of cardiac tissue of B1R⁺⁺⁺⁺-STZ and B1R⁻⁻⁻⁻-STZ showing protein levels of TAK-1 binding protein (TAB-1) and α-sarcomeric actin as well as DAPI (for cell nuclei). This demonstrates a reduced protein content of TAB-1 in B1R⁻⁻⁻⁻-STZ. B: Quantification of protein levels of the MAPK p38 and its phosphorylated form as well as TAB-1 showing a normalization of the p38 activation and the TAB-1 protein content in B1R⁻⁻⁻⁻-STZ compared with B1R⁺⁺⁺⁺-STZ. *P < 0.05 vs. B1R⁻⁻⁻⁻-STZ. (A high-quality digital representation of this figure is available in the online issue.)
inflammation by increasing invading cells and proinflammatory cytokines in airway diseases (39), we investigated its role during the development of diabetic cardiomyopathy. On one hand, in nondiabetic mice with gene deletion of the B1R, the cardiac function remained unchanged when this was compared with control mice in the current study. That is a finding that is in agreement with others (17,40–42). On the other hand, attenuated cardiac dysfunction despite severe hyperglycemia indicates a detrimental role of the B1R in diabetic cardiomyopathy when systolic and diastolic function of B1R−/−-STZ were compared with STZ.

One intracellular pathway of the B1R was shown to be dependent on the MAPK p38 (43). The current study shows an activation of the p38 pathway in the STZ group, which was normalized in the B1R−/−-STZ group. P38 phosphorylation can be induced by TAK-1 binding protein (44). In line with these findings, increased protein content of TAB-1 in diabetic wild-type mice compared with B1R−/−-STZ mice could be documented here. Since p38 activation plays a role in diabetic cardiomyopathy by inducing cardiac inflammation (45), we documented increased cardiac levels of cytokines in the STZ group, namely of IL-1β, IL-6, and TNF-α, known to cause myocardial dysfunction and mediate leukocyte infiltration during tissue inflammation (46). This cytokine induction was decreased in diabetic mice lacking the B1R.

Moreover, the number of invading immunocompetent cells was increased in the STZ group, thus yielding another marker of cardiac inflammation. These increased numbers were normalized in mice lacking the B1R. This is important, since those invading cells are one major source of cytokine production within the cardiac tissue (e.g., as shown here by the colocalization of TNF-α with CD68+ cells). Furthermore, we show that the protein levels of MMP-9 were also increased in STZ and decreased in diabetic mice with gene deletion of the B1R. Recent findings (47) suggest that especially MMP-9 modulates the transendothelial migration of leukocytes from the vessel to the tissue, where an inflammatory progress is ongoing. This can be explained by the fact that MMP-9 does not solely cleave gelatin but indeed processes and activates many chemokines and cytokines and thereby directly modulates inflammation. In line with these effects, it was shown in a mouse model of hepatitis that MMP-9 knockout mice were protected against invading leukocytes undergoing transendothelial migration (48). Only recently could it be shown that induction of MMP-9 expression is triggered by bradykinin, using cell culture rat astrocytes (49). Although those authors showed that B2R antagonism inhibited this increase (49), our data also suggest that the B1R plays a role in MMP-9 expression in cardiac tissue under diabetic conditions. Moreover, recently, the B1R was shown to be essential for IL-1β-driven cell recruitment of immunocompetent cells by inducing the chemokine CXCL-5 in endothelial cells (50). This recruitment of CXCL-5, known to be one important player in leukocyte recruitment to sites of tissue inflammation, was abolished in mice without the B1R or when a pharmacological B1R antagonist was applied (50). In line with these data, we show here that the chemokine CXCL-5 was increased under diabetic conditions. This effect was completely normalized in mice lacking the B1R despite severe hyperglycemia. The normalized levels of CXCL-5 and MMP-9 result in reduced migration of inflammatory cells into the cardiac tissue. Therefore, inflammation leading to cardiac damage due to invasion of these cells was attenuated in diabetic B1R−/−-STZ mice compared with diabetic controls with increased levels of CXCL-5 and MMP-9.

Furthermore, it was shown that the B1R, but not the B2R, increases the mRNA abundance of the profibrotic CTGF and thereby increases collagen mRNA and protein production in human fibroblasts, an effect that could be blocked by a B1R antagonist (51). Following these findings, we show increased levels of CTGF in the cardiac tissue of STZ mice, leading to increased collagen accumulation, which is known to be a hallmark in the development of diabetic cardiomyopathy leading to increased cardiac stiffness contributing to diastolic and systolic failure. Together with those findings, this mechanism could not be observed in mice with B1R gene deletion.
deletion, thus showing no increase in CTGF or collagen accumulation.

Much evidence has indicated that oxidative stress plays an important role in the failing diabetic heart (52). This can be attenuated by the kallikrein–kinin system (8,10). Consistently, we show increased nitrotyrosine and myeloperoxidase protein levels (expressed from inflammatory cells) in the cardiac tissue of the STZ group. Together with reduced inflammatory cells, nitrotyrosine and myeloperoxidase were reduced in the B1R−/−STZ group. These data suggest that the B1R might play a role in the generation of oxidative stress, most probably due to the increased recruitment of inflammatory cells resulting in increased myeloperoxidase present in the cardiac tissue. Future studies have to investigate whether this effect is only mediated by the B1R or if changes in basal B2R level expression, as shown in this study, are also influencing generation of oxidative stress in the B1R−/−STZ group.

The protein content of eNOS, known to exert antioxidative effects, was similarly reduced in both diabetic groups. Interestingly, B1R−/−STZ showed no significant downregulation on mRNA levels. Despite these changes in mRNA content, which may be explained by posttranscriptional modification, these data suggest that the diabetes-induced downregulation of eNOS protein is not mainly regulated by the B1R knockout. Again, further studies have to reveal the impact of B2R regulation on these effects. In conclusion, this study demonstrates that a lack of the B1R attenuates the development of STZ-induced diabetic cardiomyopathy with a decrease of cardiac inflammation, fibrosis, and oxidative stress.

ACKNOWLEDGMENTS

This study was supported by the Deutsche Forschungsgemeinschaft (SFB-TR-19; A2, Z3).

No potential conflicts of interest relevant to this article were reported.

The authors thank M. Kastner for proofreading the final version of the manuscript.

REFERENCES

1. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006;98:596–605
2. Westermann D, Rutschow S, Jager S, Linderer A, Ankel S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007;56:641–646
3. Zhang L, Cannell MB, Phillips AR, Cooper GJ, Ward ML. Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes 2006;57:2158–2166
4. Dorekamp M, Riad A, Stiehl S, Spillmann F, Westermann D, Jager S, Linderer A, Ankel S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007;56:641–646
5. Li J, Leschka S, Rutschow S, Schwimmerck PL, HUssmann L, Noutsias M, Westermann D, Poller W, Zeichhardt K, Klingel K, Tschope C, Schultheiss HP, Pauschinger M. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur J Pharmacol 2007;520:170–187
6. Westermann D, Van Lintouth S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, Tschope C. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2007;102:500–507
7. Yoshida H, Zhang JJ, Chao L, Chao J. Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 2000;35:25–31
8. Li HJ, Yin H, Yao YY, Shen B, Bader M, Chao L, Chao J. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation. Cardiovasc Res 2007;73:130–142
9. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003;285:H1479–H1488
10. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altman C, Chinnke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, Noutsias M: Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 19:2057–2059, 2005
11. Chao J, Yin H, Gao L, Hagiwara M, Shen B, Yang ZR, Chao L. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension 2008;52:715–720
12. Cayla C, Todiras M, Iliescu R, Saul VV, Gross V, Pizl B, Chai G, Merino VD, Spessaro JB, Baltatu OG, Bader M. Mice deficient for both kinin receptors are normotensive and protected from endothelin-induced hypotension. Proc Natl Acad Sci U S A 2000;97:8140–8145
13. Spessaro JB, Arazo RC, Peppenstall PA, Stuckey CL, Silva JA Jr, Walther T, Oliveira SM, Spessaro JL, Palva AC, Calixto JB, Levin GR, Bader M. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 2000;97:8140–8145
14. Spessaro JB, Arazo RC, Peppenstall PA, Stuckey CL, Silva JA Jr, Walther T, Oliveira SM, Spessaro JL, Palva AC, Calixto JB, Levin GR, Bader M. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 2000;97:8140–8145
15. Liesmama I, Koupappa A, Shiota N, Kokkonen JO, Kostner K, Mayranpaa M, Kovanen PT, Lindstedt KA. Increased expression of bradykinin type-1 receptors in endothelium of intramyocardial coronary vessels in human failing hearts. Am J Physiol Heart Circ Physiol 2005;288:H2317–H2322
16. Emanuelli C, Bonaria Salis M, Stacca T, Pintus G, Kirrmacher R, Isner JM, Pintus A, Gaspa L, Regoli D, Cayla C, Spessaro JB, Bader M, Madeddu P. Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation 2002;105:360–366
17. Xu J, Carrettero OA, Sun Y, Shesely E, Rhaleb NE, Liu YH, Liao TD, Yang JJ, Bader M, Yang XP. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 2005;45:747–753
18. Aihara Y, Haga J, Aihara Y, Choi J, Chao J. Kallikrein gene delivery improves serum glucose and lipid profiles and protects against angiotensin II-induced hypertension. FASEB J 2005;19:2057–2059, 2005
19. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 2007;28:1383–1388
20. Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, Pauschinger M, Potter JD, Schultheiss HP, Tschope C. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail 2006;8:115–121
21. Westermann D, Kassner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Exner M, Fiore V, Hinterhuber H, Pauwels W, Pauschinger M, Schultheiss HP, Tschope C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051–2060
22. Westermann D, Riad A, Lettau O, Roks A, Savvatis K, Becher PM, Escher F, Jan Danser AH, Schultheiss HP, Tschope C. Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail 2006;8:115–121
23. Westermann D, Van Lintouth S, Dhayat S, Dhayat N, Escher F, Bucker-Gartner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, Tschope C. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 2007;56:1834–1841
24. Howarth FC, Jacobson M, Shahbullah M, Adeghate E. Effects of insulin treatment on heart rhythm, body temperature and physical activity in streptozotocin-induced diabetic rat. Clin Exp Pharmacol Physiol 2006;33:327–331
25. Emanueli C, Salis MB, Pinnia A, Scatca T, Milia AF, Spano A, Chao J, Chao L, Sciola L, Madeddu P. Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 2002;106:1068–1075
26. Westermann D, Van Lintouth S, Dhayat S, Dhayat N, Escher F, Bucker-Gartner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, Tschope C. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 2007;56:1834–1841
27. Yao YY, Yin H, Shen B, Chao L, Chao J. Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction. Regul Pept 2007;140:12–20
28. Koch M, Spillmann F, Dendorfer A, Westermann D, Altmann C, Sahabi M, Linthout SV, Bader M, Walther T, Schultheiss HP, Tschope C. Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. Eur J Pharmacol 2006;550:143–148

29. Agata J, Chao L, Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002;40:653–659

30. Tschope C, Spillmann F, Rehfeld U, Koch M, Westermann D, Altmann C, Dendorfer A, Walther T, Bader M, Paul M, Schultheiss HP, Vetter R. Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J 2004;18:1967–1969

31. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, Pauschinger M, Pesquero JB, Bader M, Schultheiss HP, Noutsias M. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 2004;18:828–835

32. Sharma JN, Kesavarao U. Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. Immunopharmacology 1996;33:341–343

33. Lagneux C, Bader M, Pesquero JB, Demenge P, Riboult C. Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2002;2:815–822

34. Gabra BH, Berthiaume N, Siros P, Nantel F, Battistini B. The kinin system mediates hyperalgesia through the inducible bradykinin B1 receptor subtype: evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy. Biol Chem 2006;387:127–143

35. Klein J, Gonzalez J, Duchene J, Esposito L, Pradere JP, Neau E, Delage C, Calise D, Ahluwalia A, Carayon P, Pesquero JB, Bader M, Schanstra JP, Bascands JL. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 2009;23:134–141

36. Austinat M, Braeuungner S, Pesquero JB, Brede M, Bader M, Stoll G, Renne T, Kleinschnitz C. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 2009;40:285–293

37. Zhang Y, Adher M, Cardell LO. IL-1beta-induced transcriptional up-regulation of bradykinin B1 and B2 receptors in murine airways. Am J Respir Cell Mol Biol 2007;36:697–705

38. Rodriguez AI, Pereira-Flores K, Hernandez-Salinas R, Boric MP, Velarde V. High glucose increases B1-kinin receptor expression and signaling in endothelial cells. Biochem Biophys Res Commun 2006;345:652–659

39. Gama Landgraf R, Janear S, Stell AA, Siros P. Modulation of allergic and immune complex-induced lung inflammation by bradykinin receptor antagonists. Inflamm Res 2004;53:78–83

40. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, Gavras I, Gavras H. Angiotensin-converting enzyme inhibition after experimental myocardial infarction: role of the kinin B1 and B2 receptors. Hypertension 2008;51:1352–1357

41. Westermann D, Lettau O, Sobirey M, Riad A, Bader M, Schultheiss HP, Tschope C. Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. Biol Chem 2008;389:713–718

42. Xu J, Carretero OA, Shesely EG, Rhaleb NE, Yang J, Bader M, Yang XP. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol 2008;93:322–329

43. Ganju P, Davis A, Patel S, Nunez F, Fox A. p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia. Eur J Pharmacol 2001;421:191–199

44. Lu G, Kang YJ, Han J, Herschman HR, Stefani E, Wang Y. TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J Biol Chem 2006;281:6987–6995

45. Westermann D, Rutschow S, Van Linthout S, Linderer A, Buckner-Gartner C, Sobirey M, Riad A, Pauschinger M, Schultheiss HP, Tschope C. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 2006;49:2507–2513

46. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2004;54 (Suppl. 2):S114–S124

47. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480–498

48. Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, Vandenkerckhove J, Libert C. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 2001;7:1202–1208

49. Hsieh HI, Yen MH, Jou MJ, Yang CM. Intracellular signalings underlying bradykinin-induced matrix metalloproteinase-9 expression in rat brain astrocyte-I. Cell Signal 2004;16:1163–1176

50. Duchene J, Leconte F, Ahmed S, Cayla C, Pesquero J, Bader M, Perretti M, Ahluwalia A. A novel inflammatory pathway involving in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5. J Immunol 2007;179:4849–4856

51. Ricupero DA, Romero JR, Rishikof DC, Goldstein RH. Des-Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. J Biol Chem 2000;275:12475–12480

52. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, Saari JT, Cai L. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006;113:544–554